The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Official Title: Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE
Study ID: NCT03349346
Brief Summary: The primary objectives of this study are to evaluate safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of idelalisib; and to establish recommended phase 2 doses (RP2D) of idelalisib in combination with rituximab, ifosfamide, carboplatin, etoposide (RICE) in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mediastinal B-cell lymphoma (MBCL)
Detailed Description:
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospitalier Régional Universitaire de Lille, Lille, , France
Istituto Giannina Gaslini, Genova, , Italy
Ospedale Pediatrico Bambino Gesu, Roma, , Italy
Infantile Regina Margherita Hospital, Torino, , Italy
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wrocław, , Poland
Hospital Vall d´Hebrón, Barcelona, , Spain
Hospital Universitario HM Monteprincipe, Madrid, , Spain
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR